Inhibition of Mg2+ binding and DNA religation by bacterial topoisomerase I via introduction of an additional positive charge into the active site region

Nucleic Acids Research

Volumn 36, Issue 14, 2008, Pages 4788-4796

  Sorokin, Elena P ^a   Cheng, Bokun ^a   Rathi, Siddarth ^a,b   Aedo, Sandra J ^a   Abrenica, Maria V ^a,c   Tse Dinh, Yuk Ching ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WELLESLEY COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BACTERIAL PROTEIN; DNA TOPOISOMERASE; MAGNESIUM ION; METHIONINE; MUTANT PROTEIN; DIVALENT CATION; MAGNESIUM;

AMINO ACID SUBSTITUTION; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL DEATH; DNA BINDING; DNA CLEAVAGE; ENZYME ACTIVITY; ESCHERICHIA COLI; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; YERSINIA PESTIS; BINDING SITE; CATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DNA REPAIR; ENZYMOLOGY; GENETICS; METABOLISM; PH;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; YERSINIA PESTIS;

AMINO ACID SUBSTITUTION; ARGININE; BINDING SITES; CATALYSIS; CATIONS, DIVALENT; DNA CLEAVAGE; DNA TOPOISOMERASES, TYPE I, BACTERIAL; ESCHERICHIA COLI; HYDROGEN-ION CONCENTRATION; MAGNESIUM; METHIONINE; MODELS, MOLECULAR; SOS RESPONSE (GENETICS); YERSINIA PESTIS;

EID: 49249107295     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkn460     Document Type: Article

References (38)

1. Champoux,J.J. (2001) DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem., 70, 369-413.
2. Wang,J.C. (2002) Cellular roles of DNA topoisomerases: A molecular perspective, Nat. Rev. Mol. Cell Biol., 3, 430-440.
3. Forterre,P., Gribaldo,S., Gadelle,D. and Serre,M.C. (2007) Origin and evolution of DNA topoisomerases. Biochimie. 89, 427-446.
4. Corbett,K.D. and Berger,J.M. (2004) Structure, molecular mechanisms and evolutionary relationships in DNA topoisomerases. Annu. Rev. Biophys. Biomol. Struct., 33, 95-118.
5. Liu,L.F. (1989) DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58, 351-375.
6. Pommier,Y. (2006) Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer, 6, 789-802.
7. Nitiss,J.L. (2002) DNA topoisomerases in cancer chemotherapy: Using enzymes to generate selective DNA damage. Curr. Opin. Investig Drugs 3, 1512-1516.
8. Drlica,K. and Malik,M. (2003) Fluoroquinolones: Action and resistance. Curr. Top. Med. Chem., 3, 249-282.
9. Alekshun,M.N. and Levy,S.B. (2006) Commensals upon us. Biochem. Pharmacol., 71, 893-900.
10. Dorman,S.E. and Chaisson,R.E. (2007) From magic bullets back to the magic mountain: The rise of extensively drug-resistant tuberculosis. Nat. Med., 13, 295-298.
11. Furuya,E.Y. and Lowy,F.D. (2006) Antimicrobial-resistant bacteria in the community setting. Nat. Rev. Microbiol., 4, 36-45.
12. Tse-Dinh,Y.C. (2007) Exploring DNA lopoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. Infect. Disord. Drug Targets, 7, 3-9.
13. Cheng,B., Liu,I. and Tse-Dinh,Y.C. (2007) Compounds with antibacterial activity that enhance DNA cleavage by bacterial DNA topoisomrnerase I. J. Antimicrob. Chemother., 59, 640-645.
14. Aravind,L., Leipe,D.D. and Koonin,E.V. (1998) Toprim - a conserved catalytic domain in type IA and II topoisomerases, DnaG- type primases, OLD family nucleases and RecR proteins. Nucleic Acids Res., 26 4205-4213.
15. Tse-Dinh,Y.C. (1986) Uncoupling of the DNA breaking and rejoining steps of escherichia coli type I DNA topoisomerase. Demonstration of an active covalent protein-DNA complex. J. Biol. Chem., 261, 10931-10935.
16. Depew,R.E., Liu,L.F. and Wang,J.C. (1978) Interaction between DNA and escherichia coli protein omega. Formation of a complex between single-stranded DNA and omega protein. J. Biol. Chem., 253, 511-518.
17. Cheng,B., Shukla,S., Vasunilashorn,S.. Mukhopadhyay,S. and Tse-Dinh,Y.C. (2005) Bacterial cell killing mediated by topoisomerase I DNA cleavage activity. J. Biol. Chem., 280, 39489-38495.
18. Cheng,B., Sorokin,E.P. and Tse-Dinh,Y.C. (2008) Mutation adjacent to the active site tyrosine can enhance DNA cleavage and cell killing by the TOPRIM gly to ser mutant of bacterial topoisomerase I. Nucleic Acids Res., 36, 1017-1025.
19. Heitman,J. and Model,P. (1991) SOS induction as an in vivo assay of enzyme-DNA interactions. Gene, 103, 1-9.
20. Fernandez-Beros,M.E. and Tse-Dinh,Y.C. (1992) Conditional growth of escherichia coli caused by expression of vaccinia virus DNA topoisomerase I. J. Bacteriol., 174, 7059-7062.
21. Doyle,S.A. (2005) High-throughput cloning for proteomics research. Methods Mol. Biol., 310, 107-113.
22. Corn,J.E., Pease,P.J., Hura,G.L. and Berger,J.M. (2005) Crosstalk between primase subunits can act to regulate primer synthesis in trans. Mol. Cell, 20, 391-401.
23. Zhu,C.X. and Tse-Dinh,Y.C. (1999) Overexpression and purification of bacterial DNA topoisomerase I. Methods Mol. Biol., 94, 145-151.
24. Strahs,D., Zhu,C.X., Cheng,B., Chen,J. and Tse-Dinh,Y.C. (2006) Experimental and computational investigations of Ser10 and Lys13 in the binding and cleavage of DNA substrates by escherichia coli DNA topoisomerase I. Nucleic Acids Res., 34, 1785-1797.
25. Cheng,B., Feng,J., Mulay,V., Gadgil,S. and Tse-Dinh,Y.C. (2004) Site-directed mutagenesis of residues involved in G strand DNA binding by escherichia coli DNA topoisomerase I. J. Biol. Chem., 279 39207-39213.
26. Guex,N. and Peitsch,M.C. (1997) SWISS-MODEL and the swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis, 18, 2714-2723.
27. Perry,K. and Mondragon,A. (2002) Biochemical characterization of an invariant histidine involved in escherichia coli DNA topoisomerase I catalysis. J. Biol. Chem., 277, 13237-13245.
28. Zhu,C.X. and Tse-Dinh,Y.C. (2000) The acidic triad conserved in type IA DNA topoisomerases is required for binding of mg(II) and subsequent conformational change. J. Biol. Chem., 275, 5318-5322.
29. Caron,P.R. (1999) Compendium of DNA topoisomerase sequences. Methods Mol. Biol., 94, 279-316.
30. Sutherland,J.H., Cheng,B., Liu,I.F. and Tse-Dinh,Y.C. (2008) SOS induction by stabilized topoisomerase IA cleavage complex occurs via the RecBCD pathway. J. Bacteriol., 190, 3399-3403.
31. Lewinski,M.K. and Bushman,F.D. (2005) Retroviral DNA integration - mechanism and consequences. Adv. Genet., 55, 147-181.
32. Pommier,Y., Johnson,A.A. and Marchand,C. (2005) Integrase inbibitors to treat HIV/AIDS. Nature Rev. Drug Dis., 5, 236-248.
33. Asante-Appiah,E., Seeholzer,S.H. and Skalka,A.M. (1998) Structural determinants of metal-induced conformational changes in HIV-1 integrase. J. Biol. Chem., 273, 35078-35087.
34. Asante-Appiah,E. and Skalka,A.M. (1997) Molecular mechanisms in retrovirus DNA integration. Antiviral Res., 36, 139-156.
35. Kawasuji,T., Fuji,M., Yoshinaga,T., Sato,A., Fujiwara,T. and Kiyama,R. (2006) A platform for designing HIV integrase inhibitors. Part 2: A two-metal binding model as a potential mechanism of HIV integrase inhibitors. Bioorg. Med. Chem., 14, 8420-8429.
36. Long,Y.Q., Jiang,X.H., Dayam,R., Sanchez,T., Shoemaker,R., Sei,S. and Neamati,N. (2004) Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: Implication for binding to two metal ions on the active site of integrase. J. Med. Chem., 47, 2561-2573.
37. Semenova,E.A., Johnson,A.A., Marchand,C., Davis,D.A., Yarchoan,R. and Pommier,Y. (2006) Preferential inhibition of the magnesium-dependent strand transfer reaction of HIV-1 integrase by alpha-hydroxytropolones. Mol. Pharmacol., 69, 1454-1460.
38. Evering,T.H. and Markowitz,M. (2007) Raltegravir (MK-0518): An integrase inhibitor for the treatment of HIV-1. Drugs Today, 43, 865-877.